Table 1.

Descriptive statistics for HAE attack rate and TTA outcomes in treatment arms of the HELP and CHANGE studies*

	HELP			CHANGE
	Placebo (n = 41)	Lanadelumab q2w (n = 27)	Lanadelumab q4w (n = 29)	Placebo (n = 22)‡	IV C1-INH (n = 22)‡
Mean (SD) HAE attack rate per 28 days during treatment	2.45 (2.08)	0.31 (0.50)	0.60 (0.80)	4.24 (1.55)	2.09 (1.85)
Mean (SD) TTA0, days	21.41 (34.45)	97.04 (80.53)	74.90 (77.96)	4.77 (7.85)	20.68 (28.16)
Mean (SD) TTA70, days†	21.43 (28.68)	92.42 (40.04)	62.62 (46.18)	3.48 (3.41)	7.10 (4.30)

C1-INH C1-esterase inhibitor, HAE hereditary angioedema, IV intravenous, q2w every 2 weeks, q4w every 4 weeks, SD standard deviation, TTA time to attack, TTA0 time to attack after day 0, TTA70 time to attack after day 70

*These descriptive values do not account for baseline HAE attack rate or for the crossover effect of the CHANGE study

^†Sample size for CHANGE TTA70: n = 21

^‡Due to the crossover study design, every patient is considered twice